Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Astellas Pharma Inc. (ALPMY) Normalized Income after Taxes data is not available for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Normalized Income after Taxes |
-- |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$9.37B |
|
$2.29B |
|
$14.06B |
|
$23.43B |
|
$8.61B |
|
$2.68B |
|
$3.34B |
|
$11.95B |
|
$11.47B |
|
$1.80B |
|
$11.47B |
|
-- |
|
| Cash Flow Statement Financials | |
$2.32B |
|
$-298.87M |
|
$-1.60B |
|
$1.22B |
|
$1.65B |
|
$428.51M |
|
-- |
|
$-884.64M |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|